Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $42.
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $42.